US 7,320,987 B2 | ||
6-Alkoxy-pyrido-pyrimidines | ||
David Michael Goldstein, San Jose, Calif. (US); and Julie Anne Lim, San Mateo, Calif. (US) | ||
Assigned to Roche Palo Alto LLC, Palo Alto, Calif. (US) | ||
Filed on Mar. 21, 2007, as Appl. No. 11/726,339. | ||
Application 11/726339 is a division of application No. 11/503697, filed on Aug. 14, 2006, granted, now 7,196,097. | ||
Application 11/503697 is a division of application No. 11/121862, filed on May 04, 2005, granted, now 7,105,525. | ||
Application 11/121862 is a division of application No. 10/634936, filed on Aug. 05, 2003, granted, now 6,965,030. | ||
Claims priority of provisional application 60/401491, filed on Aug. 06, 2002. | ||
Prior Publication US 2007/0167484 A1, Jul. 19, 2007 | ||
Int. Cl. A01N 43/42 (2006.01); A61K 31/44 (2006.01) |
U.S. Cl. 514—299 [544/279; 546/122] | 9 Claims |
1. A method for treating rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, Crohns disease, irritable bowel
syndrome, inflammatory bowel disease, psoriasis, adult respiratory distress syndrome, asthma, or chronic obstructive pulmonary
disease, comprising: administering to a patient in need of such treatment, an effective amount of a compound of Formula I
![]() Z is CH:
X1 is O, NR4 (where R4 is hydrogen or alkyl), S or C═O:
R1 is alkyl, cycloalkyl, cycloalkylalkyl or —CH2-alkenyl:
R2 is hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, haloalkyl, heteroalkyl, cyanoalkyl, alkylene-C(O)—R21 (where R21 is hydrogen, alkyl, hydroxy, alkoxy, amino, monoalkylamino or dialkylamino), amino, monoalkylamino, dialkylamino, acyl, or
NR22—Y—R23 (where Y is —C(O), —C(O)O—, —C(O)NR24, S(O)2 or S(O)2NR25; R22, R24 and R25 are independently hydrogen or alkyl; and R23 is hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl or optionally-substituted phenyl); and
R3 is alkyl, haloalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, cycloalkyl, cycloalkylalkyl, heteroalkylsubstituted cycloalkyl,
heterosubstituted cycloalkyl, heteroalkyl, cyanoalkyl, heterocyclyl, heterocyclylalkyl, or -heterocycloamino-SO2—R12 (where R12 is haloalkyl, aryl, aryalkyl, heteroaryl or heteroaralkyl).
|